Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \>= 25 years * Polypoidal choroidal vasculopathy as noted on fluorescein and ICG angiography: active leakage, active bleeding or recent decrease in vision * BVCA using ETDRS of 20/32 to 20/400 Exclusion Criteria: * Any history of prior vitrectomy * Any prior treatment with verteporfin PDT in the study eye * Previous cataract surgery within the preceding 2 months of D0 * Active intraocular inflammation in the study eye * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * A condition, that in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease) * Participation in another investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry. * Prior anti-VEGF (Macugen, Avastin, Lucentis) in the study eye within 30 days prior to enrollment in this study * Known allergy to any component in the study drug * Uncontrolled hypertension: \>180/110 * major surgery within 28 days prior to randomization * Myocardial infarction, other cardia events requiring hospitalization within 6 months prior to randomization * Systemic anti-VEGF or pro-VEGF within 3 months of randomization * Pregnancy or lactation * History of recurrent significant infections or bacterial infections